Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

257
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
257
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

233
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
233
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

310
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
310
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

209
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
209
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

230
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
230
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

327
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
327

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atrial fibrillation detected after stroke: Recent advances and future directions.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

Feasibility and Safety of Same-Day Discharge Following Complex PCI: Sub-Analysis From a Dedicated Same-Day Discharge Radial Lounge Program.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Safety and efficacy of the Essential Pro paclitaxel drug-eluting balloon for the treatment of coronary in-stent restenosis.

REC, interventional cardiology·2025
Same author

Impact of a dedicated radial lounge on same-day discharge percutaneous coronary intervention.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2024
Same author

High-output heart failure due to arteriovenous malformation treated by endovascular embolisation.

The British journal of cardiology·2023
Same author

Venoarterial Extracorporeal Membrane Oxygenation Support for Severe Pericardial Decompression Syndrome: A Case Report.

Critical care medicine·2019

Related Experiment Video

Updated: Aug 16, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

[Interactions in antithrombotic and hypoglycemic therapy].

Julio O Bono1, Federico Liberman1, Juan P Ricarte Bratti1,2

  • 1Unidad Coronaria, Sanatorio Allende Nueva Córdoba, Córdoba, Argentina.

Medicina
|December 26, 2022
PubMed
Summary

Diabetic patients with ischemic heart disease benefit from antiplatelet therapy. This therapy interacts with oral hypoglycemic agents, offering improved glycemic control and reduced ischemic risk.

Keywords:
antidiabetic drugsantiplatelet agentscoronary artery diseasehypoglycemic drugs

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

341
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

483

Related Experiment Videos

Last Updated: Aug 16, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

341
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

483

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic patients with ischemic heart disease face elevated thrombotic risk.
  • Understanding the interplay between antiplatelet agents and oral hypoglycemic agents is crucial.

Approach:

  • This review synthesizes current knowledge on pathophysiological mechanisms in diabetic patients.
  • It examines the antithrombotic effects of oral hypoglycemic agents and their interactions with antiplatelet therapies.
  • Evidence supporting antiplatelet benefits in various ischemic heart disease scenarios is summarized.

Key Points:

  • Oral hypoglycemic agents can influence thrombotic processes and interact with antiplatelet drugs.
  • Mechanisms include improved glycemic control, enhanced nitric oxide bioavailability, and reduced oxidative stress.
  • Some agents directly inhibit platelet activation and aggregation.

Conclusions:

  • Antiplatelet therapy is beneficial for diabetic patients with ischemic heart disease.
  • The combined use of antiplatelet agents and oral hypoglycemic agents requires careful consideration of their interactions.
  • Further research into optimizing these therapeutic strategies is warranted.